HEALTHMEDPAGE TODAY
Bispecific Antibodies May Reshape Relapsed Follicular Lymphoma Care
New subgroup and real-world analyses presented at the American Society of Clinical Oncology (ASCO) meeting suggest bispecific antibodies may reshape care for relapsed follicular lymphoma, though practical questions remain. The findings add to growing evidence supporting their use in this context.
Mentioned
Related Signal
Adjacent reporting
- STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
- Supercharging Immune Cells May Help Control HIV Long-Term
- Long-lived immune cells show promise against cancer in world-first trial
- Lupus patients in England in remission after pioneering NHS trial of GM therapy
- STAT+: BeOne wins FDA approval in lymphoma race